For patient stratification, genetic biomarkers, such as mutations in the APP or PSEN1 genes, can identify individuals with familial forms of AD who might benefit from gene therapy delivered via nanocarriers (Nikolac Perkovic et al., 2021). This evidence concerns the gene APP and Alzheimer disease.